An estimated 157,000 patients died of lung cancer in the United States in the year 2000. Although surgery can be curative, only about 20% of patients are amenable to complete surgical resection. Most of the other patients are treated with radiation therapy (external-beam irradiation and/or brachytherapy) and/or chemotherapy, with less than 10% surviving to 5 years.
Most patients referred for radiation therapy have large tumor volumes requiring high doses of radiation for control of locoregional disease. Dose escalation with external-beam radiation therapy is limited by tolerance of the surrounding normal structures. Brachytherapy is one method of delivering a higher radiation dose to the tumor while sparing the surrounding normal tissues, in an attempt to improve local control. Small or occult carcinomas of the lung in medically inoperable patients are another subgroup in whom brachytherapy can be used to boost the external-beam radiation dose.
The majority of lung cancer patients eventually have symptoms related to local progression and subsequently die from locoregional failure. Commonly reported symptoms from failure of local control include cough, dyspnea, pain, and hemoptysis, with the majority related to endobronchial disease. Therefore, management of the endobronchial and peribronchial component of lung cancer is quite important, even in patients with metastatic disease. Brachytherapy can be used for palliation in these patients.
The use of brachytherapy for lung cancer is not new. Even as early as 1922, Yankauer described two cases of lung cancer treated endoscopically with radium (Ra)-226. In 1933, Graham and Singer implanted radon-222 seeds into lung tumors, and Ormerod performed transbronchial brachytherapy in 1937. The use of low-energy iodine (I)-125 reduced the radiation safety problems and regulations associated with the earlier radionuclides. Subsequently, the advent of the fiberoptic bronchoscope and the development of the high-activity iridium (Ir)-192 remote afterloader led to a significant increase in the use of endobronchial brachytherapy.
Brachytherapy may be used alone, in combination with surgery, or with external-beam radiation. The intent of treatment may be cure or palliation of symptoms.
Lung brachytherapy techniques vary widely, and only limited guidelines exist for their clinical use. The American Brachytherapy Society (ABS), therefore, formed a panel to issue guidelines specifically for the use of brachytherapy for lung carcinoma.
Selected members of the ABS with expertise in lung brachytherapy performed a literature review, which, supplemented by their clinical experience and biomathematical modeling, allowed formulation of specific recommendations and directions for future investigations in lung brachytherapy. These recommendations were made by consensus and supported by evidence in the literature, whenever possible. The consensus levels used by the ABS are similar to those of the National Comprehensive Cancer Network and are defined as follows:
Category 1: There is uniform panel consensus, based on published literature, that the recommendation is appropriate.
Category 2: Recommendation is based on low-level evidence, including nonpublished clinical experience. There is no major disagreement among panel members.
Category 3: There is major disagreement among panel members that the recommendation is appropriate.
This initial report was revised based on the comments of external experts, including some who were ABS members and some who were not. The board of directors of the ABS approved this final document.
The results of the deliberation of the panel and the ABS recommendations are given in the following sections. Unless specifically noted, these recommendations generally reflect a level 1 consensus.
Bronchoscopic and Catheter Insertion
The ABS made the following recommendations regarding bronchoscopic and catheter insertion techniques. Readers may refer to standard textbooks for procedural details.[7-9]
The ABS recommends that brachytherapy be performed with flexible fiberoptic bronchoscopy via the transnasal approach, with the patient under conscious sedation. Sedation should be administered by individuals who are properly trained and familiar with this approach. Intensive monitoring (eg, of blood pressure, pulse oximetry, and cardiac status) is required, and appropriate medical personnel and monitoring equipment (including electrocardiogram for high-risk patients) must be available.
The tumor should be visualized through the bronchoscope and photographed, if possible, for documentation and comparison on follow-up examination. The tumor location in the tracheobronchial tree, percentage of lumen occlusion, and length of airway involvement should all be recorded for dose prescription purposes.
The catheter tip should be placed at least 2 cm beyond the most distal aspect of the tumor, whenever possible. Localizing the tip in a segmental bronchus helps to hold the catheter in place. It should be noted that the endobronchial lesion is usually well visualized under bronchoscopy but not under fluoroscopy. Conversely, the catheter tip with the guidewire in place can usually be clearly seen under fluoroscopy, but the tip’s position in relation to the distal end of the tumor is harder to verify on bronchoscopy.
Graduated markings on the catheter help determine its location relative to the tumor. If premarked catheters are not available, marking the distal portion of the catheter at 5-cm intervals before insertion provides these visual reference points for catheter placement and treatment planning (category 2). Although the exact length to be treated depends on the extent of bronchial (or tracheal) involvement, lengths of 5 to 7 cm are commonly irradiated.
Centering devices (balloons, cages, and sheaths) can help to reduce dose inhomogeneity in the bronchial wall (category 2). The ABS deems centering devices to be optional, depending on physician preference.
When required by the tumor location, two or more catheters should be used to achieve adequate dosimetric coverage. In this situation, the first catheter is placed through the bronchoscope into the desired location, and the bronchoscope is withdrawn while the catheter remains in place. The bronchoscope is subsequently reintroduced, and a second catheter is placed in the desired location in the adjacent bronchus. Multiple catheters are commonly used in tumors located at the major or minor carina.
Fluoroscopy should be used to visualize the guidewire during insertion and to confirm that the catheter is not displaced as the bronchoscope is removed. The external end of the catheter should be adequately secured to the patient’s nose and marked with an ink pen at the nostril edge to allow an additional visual check that the catheter has not migrated.
Upon treatment completion and catheter removal, the patient and room should be surveyed to rule out any radioactive source misplacement. The patient should be observed after the procedure and discharged only when stable.
1. Greenlee RT, Murray T, Bolden S, et al: Cancer statistics, 2000. CA Cancer J Clin 50:7-33, 2000.
2. Yankauer S: Two cases of lung tumour treated bronchoscopically. NY Med J 21:741-742, 1922.
3. Graham EA, Singer JJ: Successful removal of an entire lung for carcinoma of the bronchus. JAMA 101:1371-1374, 1933.
4. Ormerod FC: Some notes on the treatment of carcinoma of the bronchus. J Larynx Otol 56:1-10, 1941.
5. Nag S, Abitbol AA, Anderson LL, et al: Consensus guidelines for high-dose-rate remote brachytherapy in cervical, endometrial, and endobronchial tumors. Int J Radiat Oncol Biol Phys 27:1241-1244, 1993.
6. Carlson RW, Goldstein LJ, Gradishar WJ, et al: Update of the NCCN Guidelines for Treatment of Breast Cancer. Oncology 11(11A):199-220, 1999.
7. Hilaris BS, Nori D, Anderson LL (eds): An Atlas of Brachytherapy. Clinical Applications in Cancer of the Lung, pp 184-202. New York, Macmillan, 1988.
8. Mehta MP, Lamond JP, Nori D, et al: Brachytherapy of lung cancer, in Nag S (ed): Principles and Practice of Brachytherapy, pp 323-349. Armonk, New York, Futura Publishing Co, 1997.
9. Mehta MP, Speiser BL, Macha HN: High-dose-rate brachytherapy for lung cancer, in Nag S (ed): High-Dose Rate Brachytherapy: A Textbook, pp 295-319. New York, Futura Publishing Co, 1994.
10. Kelly JF, Delclos ME, Morice RC, et al: High-dose-rate endobronchial brachytherapy effectively palliates symptoms due to airway tumors: The 10-year M. D. Anderson Cancer Center Experience. Int J Radiat Oncol Biol Phys 48:697-702, 2000.
11. Nomoto Y, Shouji K, et al: High-dose-rate endobronchial brachytherapy using a new applicator. Radiother Oncol 45(1):33-37, 1997.
12. Ezzell GA: Limitations of the straight-line assumption for endobronchial HDR brachytherapy treatments. Med Phys 27:151-153, 2000.
13. Ezzell GA: Quality assurance of treatment plans for optimized high-dose-rate brachytherapy. Med Phys 21:659-661, 1994.
14. Kubo H, Chin RB: Simple mathematical formulas for quick-checking of single-catheter high-dose-rate brachytherapy treatment plans. Endocuriether Hypertherm Oncol 8:165-169, 1992.
15. Miller AV, Davis MG, Horton JL: A method for verifying treatment times for simple high-dose-rate endobronchial brachytherapy procedures. Med Phys 23:1903-1908, 1996.
16. Rogus RD, Smith MJ, Kudo HD: An equation of QA check the total treatment time for single-catheter HDR brachytherapy of known length and dose prescription depth. Int J Radiat Oncol Biol Phys 40:245-248, 1998.
17. Ezzell GA: A manual algorithm for computing dwell times for two-catheter endobronchial treatments using HDR brachytherapy. Med Phys 27:1030-1033, 2000.
17a. Nag S, Samsami N: Pitfalls of inappropriate optimization. J Brachyther Intl 16:187-198, 2000.
18. Gaspar LE: Brachytherapy in lung cancer. J Surg Oncol 67(1):60-70, 1998.
19. Speiser BL: Brachytherapy in the treatment of thoracic tumors. Lung and Esophageal. Hematol Oncol Clin North Am 13(3):609-634, 1999.
20. Lo TCM, Beamis JF Jr, Weinstein RS, et al: Intraluminal low-dose-rate brachytherapy for malignant endobronchial obstruction. Radiother Oncol 23:16-20, 1992.
21. Locken P, Dillon M, Patel P, et al: Palliation of locally recurrent non-small-cell lung cancer with low-dose-rate iridium-192 endobronchial implant combined with localized external-beam irradiation. Endocurie Hypertherm Oncol 6:217-222, 1990.
22. Mehta M, Petereit D, Chosy L, et al: Sequential comparison of low-dose-rate and hyperfractionated high-dose-rate endobronchial radiation for malignant airway occlusion. Int J Radiat Oncol Biol Phys 23(1):133-139, 1992.
23. Paradelo JC, Waxman MJ, Throne IJ, et al: Endobronchial irradiation with 192Ir in the treatment of malignant endobronchial obstruction. Chest 102:1072-1074, 1992.
24. Raju PI, Roy T, McDonald RD, et al: Low-dose-rate endobronchial brachytherapy in the treatment of malignant airway obstruction. Int J Radiat Oncol Biol Phys 27:667-680, 1993.
25. Roach M, Leidholdt EM, Tater BS, et al: Endobronchial radiation therapy in the management of lung cancer. Int J Radiat Oncol Biol Phys 18:1449-1454, 1990.
26. Schray MF, McDougall JC, Martinez A, et al: Management of malignant airway compromise with laser and low-dose-rate brachytherapy. Chest 93:264-269, 1988.
27. Aygun C, Weiner S, Scariato A, et al: Treatment of non-small-cell lung cancer with external beam: Radiotherapy and high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 23:127-132, 1992.
28. Bedwinek J, Petty A, Bruton C: The use of high-dose-rate endobronchial brachytherapy to palliate symptomatic endobronchial recurrence of previously irradiated bronchogenic carcinoma. Int J Radiat Oncol Biol Phys 22:23-30, 1992.
29. Burt PA, O’Driscoll BR, Notley HM, et al: Intraluminal irradiation for the palliation of lung cancer with high-dose-rate microselectron. Thorax 45:765-768, 1990.
30. Chang LFL, Horvath J, Peyton W, et al: High-dose rate afterloading brachytherapy in malignant airway obstruction of lung cancer. Int J Radiat Oncol Biol Phys 28:211-212, 1992.
31. Delclos ME, Komaki R, Garden A, et al: High-dose-rate remote afterloading endobronchial brachytherapy for recurrent endobronchial lesions. Radiology 281:279-282, 1996.
32. Macha HN, Wahlers B, Reichle C, et al: Endobronchial radiation therapy for obstructing malignancies: Ten years’ experience with iridium-192 high-dose radiation brachytherapy afterloading technique in 365 patients. Lung 173:271-280, 1995.
33. Miller JI Jr, Phillips TW: Neodymium: YAG laser and brachytherapy in the management of inoperable bronchogenic carcinoma. Ann Thorac Surg 50(2):190-196, 1990.
34. Speiser B, Spratling L: Intermediate-dose-rate remote afterloading brachytherapy for intraluminal control of bronchogenic carcinoma. Int J Radiat Oncol Biol Phys 18:1443-1448, 1990.
35. Stout R, Barber PV, Burt PA, et al: Intraluminal brachytherapy in bronchial carcinoma (abstract). Br J Radiol 63:16, 1990.
36. Sutedja G, Baris G, Schaake-Koning C, et al: High-dose-rate brachytherapy in patients with local recurrence after radiotherapy of non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 24:551-553, 1992.
37. Zajac AJ, Kohn ML, Heiser D, et al: High-dose-rate intraluminal brachytherapy in the treatment of endobronchial malignancy. Radiology 187:571-575, 1993.
38. Nag S, Gupta N: A simple method of obtaining equivalent doses for use in HDR brachytherapy. Int J Radiat Oncol Biol Phys 46:507-513, 2000.
39. Kohek PH, Pakisch B: Intraluminal irradiation in the treatment of malignant airway obstruction. Eur J Surg Oncol 20(6):674-680, 1994.
40. Edell ES, Cortese DA, McDougall JC: Ancillary therapies in the management of lung cancer: Photodynamic therapy, laser therapy, and endobronchial prosthetic devices. Mayo Clin Proc 68:685-690, 1993.
41. Prakash U: Advances in bronchoscopic procedures. Chest 116(5):1403-1408, 1999.
42. Dumon J: A dedicated tracheobronchial stent. Chest 97:328-332, 1990.
43. Bollinger C, Heitz M: An airway wall stent for the treatment of tracheobronchial malignancies. Thorax 51:1127-1129, 1996.
44. Cortese D, Edell E: Photodynamic therapy for early stage squamous cell carcinoma of the lung. Mayo Clin Proc 72:595-602, 1997.
45. Furuta M, Tsukiyama I, Ohno T, et al: Radiation therapy for roentogenographically occult lung cancer by external-beam irradiation and endobronchial high-dose-rate brachytherapy. Lung Cancer 25:183-189, 1999.
46. Perol M, Caliandro R, Pommier P, et al: Curative irradiation of limited endobronchial carcinomas with high-dose-rate brachytherapy. Results of a pilot study. Chest 111(5):1417-1423, 1997.
47. Saito M, Yokoyama A, Kurita Y, et al: Treatment of roentgenographically occult endobronchial with external-beam radiotherapy and intraluminal low-dose-rate brachytherapy: Second report. Int J Radiat Oncol Biol Phys 47:673-680, 2000.
48. Sutedja G, Baris G, van Zandwijk N: High-dose-rate brachytherapy has a curative potential in patients with intraluminal squamous cell lung cancer. Respiration 61:167-168, 1994.
49. Tredaniel J, Hennequin C, Zalcman G, et al: Prolonged survival after high-dose-rate endobronchial radiation for malignant airway obstruction. Chest 105:767-772, 1994.
50. Chang LFL: High-dose-rate afterloading intraluminal brachytherapy in malignant airway obstruction of lung cancer. Int J Radiat Oncol Biol Phys 28:589-596, 1994.
51. Cotter GW, Craig L, Ellingwood KE, et al: Inoperable endobronchial obstructing lung cancer treated with combined endobronchial and external-beam irradiation: A dosimetric analysis. Int J Radiat Oncol Biol Phys 27:531-535, 1993.
52. Huber RM, Fischer R, Haútmann H, et al: Does additional brachytherapy improve the effect of external irradiation? A prospective, randomized study in central lung tumors. Int J Radiat Oncol Biol Phys 38(3):533-540, 1997.
53. Reddi RP, Marbach JC: HDR remote afterloading brachytherapy of carcinoma of the lung. Selectron Brachyther J 6(1):21-23, 1992.
54. Marsiglia H, Baldeyrou P, Lartigau E ,et al: High-dose-rate brachytherapy as a sole modality for early-stage endobronchial carcinoma. Int J Radiat Oncol Biol Phys 47:665-672, 2000.
55. Brach B, Buhler C, Hayman MH, et al: Percutaneous computed tomography-guided fine-needle brachytherapy of pulmonary malignancies. Chest 106:268-274, 1994.
56. Chen A, Galloway M, Landreneau R, et al: Intraoperative 125I brachytherapy for high-risk stage I non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 44(5):1057-1063, 1999.
57. Fleischman EH, Kagan R, Streeter OE, et al: Iodine-125 interstitial brachytherapy in the treatment of carcinoma of the lung. J Surg Oncol 49:25-28, 1992.
58. Hilaris BS, Martini N, Wong GY, et al: Treatment of superior sulcus tumor (Pancoast tumor). Surg Clin North Am 67:965-977, 1987.
59. Hilaris BS, Martini N: Interstitial brachytherapy in cancer of the lung: 20 year experience. Int J Radiat Oncol Biol Phys 5:1956-1976, 1979.
60. Hilaris BS, Martini N: Current state of intraoperative interstitial brachytherapy in lung cancer. Int J Radiat Oncol Biol Phys 15:1347-1354, 1988.
61. Hilaris BS, Nori D, Martini N: Results of radiation therapy in stage I and II unresectable non-small-cell lung cancer. Endocuriether Hypertherm Oncol 2:15-21, 1986.
62. Horowitz BS, Lewis J, Bae Y, et al: Combined surgery, brachytherapy, and external irradiation in the treatment of non-oat-cell cancer of the lung: Preliminary report. Endocurieth Hypertherm Oncol 3:31-36, 1987.
63. Nag S, Rekha G, Tai DL, et al: Interstitial radiation implantation for unresectable non-oat-cell carcinoma of the lung. Am Surg 51:482-486, 1985.
64. Pisch J, Harvey JC, Panigrahi N, et al: Iodine-125 volume implants in patients with medically unresectable stage I lung cancer. Endocuriether Hypertherm Oncol 12:165-170, 1996.
65. Hilaris BS, Mastoras D: Contemporary brachytherapy approaches in non-small-cell lung cancer. J Surg Oncol 69(4):258-264, 1998.
66. Nag S: Brachytherapy for lung cancer: Cancer treatment symposia 1:49-56, 1985.
67. Nori D: Intraoperative brachytherapy in non-small-cell lung cancer. Semin Surg Oncol 9(2):99-107, 1993.
68. Beyer D, Nath R, Butler W, et al: American Brachytherapy Society Recommendations for Clinical Implementation of NIST-1999 Standards for 103Palladium Brachytherapy. Int J Radiat Oncol Biol Phys 47:273-275, 2000.
69. Nag S, Beyer D, Friedland J, et al: American Brachytherapy Society (ABS) Recommendations for Transperineal Permanent Brachytherapy of Prostate Cancer. Int J Radiat Oncol Biol Phys 44:789-799, 1999.
70. Nath R, Anderson LL, Luxton G, et al: Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Committee Task Group No. 43. Med Phys 22:209-234, 1995.
71. Nag S, Martinez-Monge R, Gupta N: Intraoperative radiation therapy using electron-beam and high-dose-rate brachytherapy. Cancer J 10:94-101, 1997.
72. Nag S, Martínez-Monge R, Ruymann FB, et al: Feasibility of intraoperative high-dose rate brachytherapy to boost low-dose external beam radiation therapy to treat pediatric soft-tissue sarcomas. Med Pediatr Oncol 31:79-85, 1998.
73. Gollins SW, Burt PA, Stout R: High dose rate intraluminal radiotherapy for carcinoma of the bronchus: Outcome of treatment of 406 patients. Radiother Oncol 33:31-40, 1994.
74. Gustafson G, Vicini F: High dose rate endobronchial brachytherapy in the management of primary and recurrent bronchogenic malignancies. Cancer 75(9):2345-2350, 1995.
75. Hennequin C, Tredaniel J: Predictive factors for late toxicity after endobronchial brachytherapy: A multivariate analysis. Int J Radiat Oncol Biol Phys 42(1):21-27, 1998.
76. Nori D, Allison R, Kaplan B, et al: High dose rate intraluminal irradiation in bronchogenic carcinoma. Chest 104:1006-1011, 1993.
77. Ornadel D, Duchesne G: Defining the roles of high dose rate endobronchial brachytherapy and laser resection for recurrent bronchial malignancy. Lung Cancer 16(2-3):203-213, 1997.
78. Speiser BL, Spratling L: Remote afterloading brachytherapy for the local control of endobronchial carcinoma. Int J Radiat Oncol Biol Phys 25:579-587, 1993.
79. Taulelle M, Chauvet B, Vincent P, et al: High-dose rate endobronchial brachytherapy: Results and complications in 189 patients. Eur Respir J 11(1):162-168, 1998.
80. Kohek P, Pakisch B, Rehak P, et al: Nd-YAG laser debulking combined with 192Ir HDR brachytherapy for obstructing cancer of the central bronchial airways: Technique and results. Selectron Brachyther J S1:45-47, 1990.